Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Safety reporting proposed reg

This article was originally published in The Tan Sheet

Executive Summary

FDA will accept comments until Oct. 14 on its proposed rule amending premarketing and postmarketing safety reporting requirements for drugs. Original comment deadline for the reg was July 14, but agency received a request for a 90-day extension, which it deems "appropriate, given the length and complexity of the proposed rule." The 1safety reporting proposed rule, which would encourage more reporting of foreign safety data and premarketing adverse events, was published March 14 (2"The Tan Sheet" March 24, 2003, p. 12)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel